tiprankstipranks
Trending News
More News >
Vectus Biosystems Limited (AU:VBS)
ASX:VBS
Australian Market
Advertisement

Vectus Biosystems Limited (VBS) AI Stock Analysis

Compare
2 Followers

Top Page

AU:VBS

Vectus Biosystems Limited

(Sydney:VBS)

Rating:40Underperform
Price Target:
AU$0.00
▼(-100.00%Downside)
Vectus Biosystems Limited's overall stock score is driven largely by its poor financial performance and valuation. The company's persistent financial challenges and negative earnings impact its attractiveness to investors. While technical analysis indicates some short-term bullish momentum, the overbought conditions suggest potential downside risks. The lack of earnings call and corporate events data means no additional insights were available to affect the score.

Vectus Biosystems Limited (VBS) vs. iShares MSCI Australia ETF (EWA)

Vectus Biosystems Limited Business Overview & Revenue Model

Company DescriptionVectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.
How the Company Makes MoneyVectus Biosystems Limited generates revenue primarily through the development and potential commercialization of its proprietary drug candidates. The company invests in extensive research and development to advance its product pipeline, with a key focus on VB0004. Revenue is expected to be derived from licensing agreements, partnerships with pharmaceutical companies, and potential sales of approved drugs. Strategic collaborations and partnerships play a significant role in funding Vectus' research initiatives and expanding its market reach. The company may also receive milestone payments and royalties from licensing its drug candidates to other entities as they progress through clinical trials and into commercialization.

Vectus Biosystems Limited Financial Statement Overview

Summary
Vectus Biosystems Limited is facing significant financial challenges, characterized by declining revenues, persistent losses, and negative equity. The company needs strategic initiatives to enhance revenue and manage costs effectively.
Income Statement
40
Negative
Vectus Biosystems Limited has demonstrated a declining revenue trend with a negative revenue growth rate from 2023 to 2024. The company is struggling with profitability, reflected in negative net profit and EBIT margins. Despite some gross profit, the overall financial performance remains weak due to high operating losses.
Balance Sheet
35
Negative
The balance sheet shows a significant improvement in debt levels, but the company still faces challenges with negative equity, indicating long-term financial instability. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio remains negative, undermining financial stability.
Cash Flow
45
Neutral
The cash flow statement highlights negative operating and free cash flows, with slight improvement in free cash flow from the previous year. The company exhibits a weak operating cash flow to net income ratio, indicating inefficient cash conversion from operations.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue1.14M1.35M1.30M180.0051.19K
Gross Profit1.14M1.31M1.28M1.02M31.67K
EBITDA-2.27M-3.19M-3.28M-3.71M-2.64M
Net Income-2.34M-3.45M-3.99M-3.86M-3.00M
Balance Sheet
Total Assets2.03M4.63M3.94M6.98M3.00M
Cash, Cash Equivalents and Short-Term Investments808.97K2.95M1.28M5.78M2.72M
Total Debt28.93K70.21K6.90M8.68M8.28M
Total Liabilities539.26K1.11M8.36M9.88M9.71M
Stockholders Equity1.49M3.52M-4.42M-2.90M-6.71M
Cash Flow
Free Cash Flow-2.10M-2.37M-4.46M-3.26M-3.00M
Operating Cash Flow-2.03M-2.35M-4.44M-3.26M-3.00M
Investing Cash Flow-67.90K-17.13K-21.00K0.000.00
Financing Cash Flow-41.28K4.04M-34.55K6.35M5.64M

Vectus Biosystems Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.06
Price Trends
50DMA
0.05
Positive
100DMA
0.06
Negative
200DMA
0.07
Negative
Market Momentum
MACD
<0.01
Negative
RSI
82.50
Negative
STOCH
95.83
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VBS, the sentiment is Neutral. The current price of 0.06 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 82.50 is Negative, neither overbought nor oversold. The STOCH value of 95.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:VBS.

Vectus Biosystems Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.61B0.11-63.03%2.07%16.35%0.29%
40
Underperform
AU$2.93M-163.00%9.19%
$2.18M-119.28%
AU$4.84M-983.90%
46
Neutral
AU$2.23M-392.18%34.26%
40
Underperform
AU$2.17M-45.96%-26.67%
27
Underperform
AU$1.28M-147.32%26.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:VBS
Vectus Biosystems Limited
0.06
-0.04
-40.00%
BITRF
Biotron
0.01
-0.01
-50.00%
AU:CMB
Regeneus Ltd.
0.26
-0.14
-35.00%
AU:1AD
AdAlta Ltd.
0.01
-0.01
-50.00%
AU:ANR
Anatara Lifesciences Ltd
0.01
-0.04
-80.00%
AU:HXL
Hexima Ltd
0.01
-0.01
-50.00%

Vectus Biosystems Limited Corporate Events

Vectus Biosystems Expands Share Issuance Under Employee Incentive Plan
Jul 17, 2025

Vectus Biosystems Limited has issued 55,019 new fully paid ordinary shares to an employee under its Employee Incentive Plan. This move reflects the company’s ongoing efforts to incentivize its workforce and align employee interests with corporate goals, potentially impacting its operational dynamics and stakeholder relations.

Vectus Biosystems Expands Capital with New Securities Issuance
Jul 17, 2025

Vectus Biosystems Limited has announced the issuance of 55,019 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure, potentially impacting its financial flexibility and market presence positively.

Vectus Biosystems Issues Unquoted Options to Employees
Jun 27, 2025

Vectus Biosystems Limited announced the issuance of 75,000 unquoted options as part of an employee incentive scheme. This move is likely aimed at retaining talent and aligning employee interests with company growth, potentially impacting the company’s operational dynamics and stakeholder relations positively.

Vectus Biosystems Advances VB0004 Commercialization and Seeks Chinese Collaborations
Apr 30, 2025

Vectus Biosystems Limited has been actively advancing its commercialization efforts for its lead compound, VB0004, and other drug candidates, with a focus on potential collaborations in China. The company has validated VB0004’s safety profile in recent clinical trials and is exploring faster approval paths in China. Financially, Vectus has reduced operating costs and is seeking licensing opportunities to support further clinical studies, with cash-on-hand reported at $370,000 as of March 2025.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025